Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.
OBJECTIVE
To describe the range and attribution of neuropsychiatric (NP) disease in an unselected cohort of patients with systemic lupus erythematosus (SLE) and to examine the association with cumulative organ damage, medication use, and quality of life.


METHODS
One hundred eleven patients with SLE in a single referral center were studied. NP syndromes were defined using the American College of Rheumatology (ACR) nomenclature and case definitions. Overall disease activity was measured by the SLE Disease Activity Index (SLEDAI); cumulative organ damage was determined by the ACR/SLICC damage index; and quality of life by the SF-36.


RESULTS
Patients' mean age was 44.7 years, 87% were female, and 92% were Caucasian. The mean (+/- SE) disease duration was 10.1 +/- 0.7 years. A total of 74 NP events were identified in 41 of 111 (37%) patients. Thirteen of the 19 ACR NP syndromes were identified and 2 or more NP manifestations occurred in 56% of patients. Central nervous system manifestations accounted for 92% of the events compared to involvement of the peripheral nervous system in 8%. Thirty-five (47%) of these events were attributed entirely to SLE, 30 (41%) were attributed exclusively to non-SLE factors, and in the remaining 9 events (12%) both SLE and non-SLE factors were felt to be contributory. Cumulative organ damage was higher in patients with NP disease, although this was not statistically significant and they were more likely to have received prednisone or immunosuppressive drugs (p < 0.05). Patients with NP disease reported more fatigue (p < 0.05) and had significantly lower scores on 7 of 8 subscales of the SF-36 (p < 0.05). These associations were found regardless of the attribution of NP disease. In contrast, the occurrence of renal disease in the same cohort of patients was not associated with lower SF-36 scores or fatigue.


CONCLUSIONS
In patients with SLE, NP disease has diverse manifestations and can be attributed to lupus in roughly half of the cases. The occurrence of NP disease is associated with more frequent use of corticosteroids and immunosuppressive drugs. In contrast to other serious manifestations of SLE, such as renal disease, NP disease is associated with a significant reduction in quality of life.
Hanly
John G
JG
Division of Rheumatology, Department of Medicine, Queen Elizabeth II Health Sciences Center and Dalhousie University, Halifax, Nova Scotia, Canada. john.hanly@cdha.nshealth.ca
McCurdy
Grace
G
Fougere
Lisa
L
Douglas
Jo-Anne
JA
Thompson
Kara
K
D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use; D002490:Central Nervous System / Q000473:pathology*; D005221:Fatigue / Q000209:etiology / Q000473:pathology; D005260:Female; D006304:Health Status; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007674:Kidney Diseases / Q000209:etiology / Q000473:pathology; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D008181:Lupus Nephritis / Q000150:complications / Q000473:pathology*; D020945:Lupus Vasculitis, Central Nervous System / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D008297:Male; D009674:Nova Scotia; D017933:Peripheral Nervous System / Q000473:pathology*; D011788:Quality of Life; D012720:Severity of Illness Index
D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents